Karyopharm (KPTI) insider: PSUs vest on SENTRY enrollment; small tax-driven sale
Rhea-AI Filing Summary
Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), reported the vesting of performance-based restricted stock units and a small subsequent sale. On September 12, 2025 the company certified that the clinical milestone for complete enrollment in its Phase 3 SENTRY trial had been achieved, resulting in 46 earned PSUs (each convertible into one share) which vested that day. The reporting line shows 10,431 shares beneficially owned following vesting (including 922 shares acquired via the ESPP on April 30, 2025). On September 15, 2025 the reporting person sold 23 shares at $6.43 per share under a pre-established automatic sale instruction to satisfy tax withholding obligations.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider vesting and tax-driven sale tied to a certified clinical trial enrollment milestone.
The filing documents the conversion of 46 performance-based RSUs into vested shares following certification that the Phase 3 SENTRY trial reached complete enrollment. That operational milestone is company-identified and triggered the PSU payout; the insider retained the vast majority of shares and executed a small, non-discretionary sale of 23 shares at $6.43 to cover withholding taxes. For investors, this is an administrative insider event rather than a directional trading signal.
TL;DR: Proper disclosure of vested PSUs and a pre-arranged sale plan demonstrates standard governance and tax compliance.
The filing indicates the Compensation Committee certified a clinical enrollment milestone that materially satisfied vesting conditions for performance RSUs awarded in February 2023. The sale of a small number of shares was executed under a previously adopted durable automatic sale instruction, which the filing discloses. The form is complete, signed by an attorney-in-fact, and follows required Section 16 reporting conventions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 23 | $6.43 | $147.89 |
| Grant/Award | Common Stock | 46 | $0.00 | -- |
Footnotes (1)
- Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025. Includes 922 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2025. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
